Skip to main content
Terug
TGTX logo

TG Therapeutics, Inc.

Datakwaliteit: 100%
TGTX
NASDAQ Healthcare Biotechnology
€ 30,45
▲ € 0,38 (1,26%)
Marktkapitalisatie: 4,86B
Dagbereik
€ 29,91 € 30,81
52-Weeksbereik
€ 25,28 € 46,48
Volume
1.912.970
50D / 200D Gem.
€ 29,56 / € 32,33
Vorige Slotkoers
€ 30,07

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 10,9 0,4
P/B 7,5 2,9
ROE % 102,8 3,7
Net Margin % 72,6 3,8
Rev Growth 5Y % 209,8 10,0
D/E 0,4 0,2

Belangrijkste Punten

Revenue grew 209,82% annually over 5 years — strong growth
Earnings grew 1812,41% over the past year
ROE of 102,75% indicates high profitability
Net margin of 72,56% shows strong profitability
Debt/Equity of 0,40 — conservative balance sheet
Negative free cash flow of -24,99M

Groei

Revenue Growth (5Y)
209,82%
Revenue (1Y)87,32%
Earnings (1Y)1812,41%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
102,75%
ROIC10,18%
Net Margin72,56%
Op. Margin20,01%

Veiligheid

Debt / Equity
0,40
Current Ratio4,10
Interest Coverage4,61

Waardering

P/E Ratio
10,87
P/B Ratio7,50
EV/EBITDA40,90
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 87,32% Revenue Growth (3Y) 62,40%
Earnings Growth (1Y) 1812,41% Earnings Growth (3Y) 494,04%
Revenue Growth (5Y) 209,82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 616,29M Net Income (TTM) 447,18M
ROE 102,75% ROA 42,06%
Gross Margin 83,62% Operating Margin 20,01%
Net Margin 72,56% Free Cash Flow (TTM) -24,99M
ROIC 10,18% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,40 Current Ratio 4,10
Interest Coverage 4,61 Dividend Yield 0,00%
Valuation
P/E Ratio 10,87 P/B Ratio 7,50
P/S Ratio 7,89 PEG Ratio 0,01
EV/EBITDA 40,90 Dividend Yield 0,00%
Market Cap 4,86B Enterprise Value 5,04B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 616,29M 329,00M 233,66M 2,79M 6,69M
Net Income 447,18M 23,38M 12,67M -223,81M -348,10M
EPS (Diluted) 2,77 0,15 0,09 -1,46 -2,63
Gross Profit 515,33M 290,52M 219,53M 2,52M 5,90M
Operating Income 123,32M 41,93M 20,63M -218,32M -344,77M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,06B 577,69M 329,59M 193,57M 379,63M
Total Liabilities 415,23M 355,33M 169,09M 134,99M 142,48M
Shareholders' Equity 648,02M 222,36M 160,50M 58,59M 237,15M
Total Debt 260,73M 253,72M 110,80M 83,06M 79,05M
Cash & Equivalents 79,15M 179,89M 92,93M 102,30M 298,89M
Current Assets 630,76M 566,36M 317,94M 168,27M 330,97M
Current Liabilities 153,76M 90,68M 53,72M 53,20M 65,38M

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Contrarian Investing (David Dreman)
#86 of 658
59
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#159 of 326
52
Growth Growth Investing (Philip Fisher)
#3 of 154
100
Custom Full Throttle
#44 of 146
54

Recente Activiteit

Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt Full Throttle
Mar 24, 2026